📰 Open Label Study News
Page 6 - Open Label Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Open Label Study. Real-time updates on events, politics, business and more.
April 27, 2022
Investegate announcements from Redx Pharma plc, Redx to Present at ASCO
March 25, 2022
Maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022
March 25, 2022
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue
December 3, 2021
/PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing...
December 3, 2021
/PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing...
October 5, 2021
Read the latest National Institutes of Health headlines, on NewsNow: the one-stop shop for National Institutes of Health news
May 13, 2021
Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021 Clostridioides difficile Infection With and Without Sepsis Presenting Author: Alpesh Amin, MD, MBA, Thomas Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California Irvine EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET DDW has made abstracts available o...
January 6, 2021
Posted on 312 Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of neurodegenerative diseases, including its lead candidate Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC), today announced initial data from its “Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol ® Cyclo™ (HPBCD) ...